Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are commonly used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Eastern Africa, the market for these drugs is developing in a particular way due to various factors.
Customer preferences: In Eastern Africa, there is a growing demand for bronchodilator drugs due to the high prevalence of respiratory diseases in the region. Asthma and COPD are particularly prevalent in urban areas due to air pollution and smoking. Patients in the region prefer quick-relief inhalers that provide immediate relief from symptoms.
Trends in the market: The bronchodilator drugs market in Eastern Africa is growing due to the increasing prevalence of respiratory diseases. The demand for quick-relief inhalers is increasing, and pharmaceutical companies are responding by introducing new products that cater to this demand. The market is also seeing the introduction of combination inhalers that contain both a bronchodilator and a steroid, which provides both quick relief and long-term control of symptoms.
Local special circumstances: One of the unique factors in the Eastern African market is the high prevalence of traditional medicine use. Many patients in the region prefer to use traditional remedies for respiratory diseases, which can limit the growth of the bronchodilator drugs market. However, as more patients become aware of the benefits of modern medicine, the market is expected to grow.
Underlying macroeconomic factors: The healthcare infrastructure in Eastern Africa is improving, which is contributing to the growth of the bronchodilator drugs market. Governments in the region are investing in healthcare and increasing access to medical facilities. The increasing urbanization in the region is also contributing to the growth of the market as more people are exposed to air pollution and smoking. The growing middle class in the region is also driving demand for better healthcare and access to modern medicine.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
